Biotech Firms Century Therapeutics, PolyPid Exceed EPS Estimates

Century Therapeutics reported a GAAP EPS of -$0.11, beating estimates by $0.06, while PolyPid announced a GAAP EPS of -$0.35, surpassing estimates by $0.08. Both biotechnology companies thus exceeded their respective earnings per share forecasts.